Last reviewed · How we verify
Naftin 1% Cream
Naftin (naftifine) is a topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.
Naftin (naftifine) is a topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane. Used for Tinea pedis (athlete's foot), Tinea cruris (jock itch), Tinea corporis (ringworm).
At a glance
| Generic name | Naftin 1% Cream |
|---|---|
| Sponsor | Merz North America, Inc. |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Naftifine is an allylamine-class antifungal that selectively inhibits squalene epoxidase, an enzyme critical for ergosterol synthesis in fungal cell membranes. By depleting ergosterol and accumulating toxic sterol precursors, it causes fungal cell membrane instability and death. It has broad-spectrum activity against dermatophytes, yeasts, and some non-dermatophyte molds.
Approved indications
- Tinea pedis (athlete's foot)
- Tinea cruris (jock itch)
- Tinea corporis (ringworm)
Common side effects
- Local irritation (burning, stinging, erythema)
- Pruritus
- Dryness
Key clinical trials
- Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris (PHASE3)
- Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (PHASE1)
- Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naftin 1% Cream CI brief — competitive landscape report
- Naftin 1% Cream updates RSS · CI watch RSS
- Merz North America, Inc. portfolio CI